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Abstract 
Haplo-identical transplants (Haplo-Tx) are an important alternative for patients with hematological malignancies who   
lack a HLA-identical donor. Seventy-one T-replete Haplo-Tx were performed in 70 high-risk patients at our center; 22/ 
70 (31%) patients with refractory/relapsed leukemia received sequential salvage therapy (SeqTh) with high-dose 
chemotherapy followed by Haplo-Tx during the chemotherapy-induced neutropenia. Graft-versus-host disease 
(GVHD) prophylaxis consisted of post-transplant cyclophosphamide (days + 3 and + 4) with tacrolimus and mycophe- 
nolic acid. After a median follow-up of 29.2 months, 3-year overall survival (OS) and event-free survival (EFS) were 
43.8 and 40.2%, while 3-year cumulative incidences (CIs) of  non-relapse mortality  (NRM)  and relapse (RI)  were 27  
and 33%. Day 100 and day 400 CI of grade III–IV acute and moderate-severe chronic GVHD were 11 and 15%. Three-
year RI was significantly lower in patients in complete remission (CR) versus those not in CR at the time of transplant 
(21.5 vs. 48%, p = 0.009) and in patients who received PBSC as compared to BM (22 vs. 45%, p = 0.009).       In patients 
treated with SeqTh, 3-year OS was 19%, while 3-year RI and NRM were  52  and  28%  at  a  median  follow-up of 50 
months. Overall, Haplo-Tx was feasible in heavily pretreated high-risk patients without a suitable HLA-identical donor. 
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Introduction 
 
Allografting is potentially curative for several hematological 
malignancies. Donor availability remains a major limitation. 
A HLA-identical sibling is currently considered the optimal 
donor at most centers. However, approximately only one third 
of the patients of Caucasian origin eventually find one in the 
family and 70% find a suitable unrelated donor. These figures 
are lower for individuals of ethnic minorities [1, 2]. Family 
haplo-identical donors and umbilical cord blood (UCB) units 
have become important alternatives for those patients without 
a suitable HLA-matched donor. 
Haplo-identical hematopoietic stem cell transplantation 
(Haplo-Tx) is associated with intense bi-directional 
allo-reactivity. Different programs with both T-cell depleted 
(TCD) and T-cell repleted modalities were proposed over the 
decades to prevent graft vs. host disease (GVHD) while 
  
 
sparing the graft vs. leukemia effects. High rates of non- 
relapse mortality (NRM) were however observed [3, 4]. 
Table 1 Patients and transplants characteristics  
 
N (%) 
More recently, other Haplo-Tx strategies were developed [5]    
either by refinements of T-cell depletion [6–8] or by intensi- 
fied immune suppression [9–11]. The currently most com- 
monly used T-cell replete (TCR) Haplo-Tx modality was 
pioneered by the Johns Hopkins group. In this setting, the 
administration of post-transplant cyclophosphamide (PT-Cy) 
plays a pivotal role [12–20]. Preclinical studies showed that 
PT-Cy targets allo-reactive T-cells generated early after 
Haplo-Tx, sparing non-dividing lymphocytes and hematopoi- 
etic stem cells mainly due to increased expression of protec- 
tive aldehyde dehydrogenase (ALDH) [21–23]. In particular, 
Tregs resistance to cyclophosphamide was recently correlated 
with lower GVHD rates [24, 25]. 
At our center, the preferred alternative for patients who lack 
a HLA-identical sibling has been a HLA-matched or partially 
matched (8/8 or 7/8 matched) unrelated donor. In 2010, we 
implemented a Haplo-Tx program with PT-Cy for high-risk 
patients without a suitable donor. Here, we report our experi- 
ence that helped to define our center policy. 
 
 
Patients and methods 
 
Patients 
 
Seventy-one Haplo-Tx were performed in 70 patients with 
high-risk hematological malignancies at the Transplant 
Center of the Department of Oncology, Presidio Molinette, 
AOU Città della Salute e della Scienza di Torino, Torino, 
Italy, between January 2010 and January 2017. Fourteen pa- 
tients, with shorter follow-up, were also part of a retrospective 
registry study by the European Bone Marrow Transplantation 
Group (EBMT) [26]. Patient and disease characteristics are 
summarized in Table 1. The hematopoietic cell transplantation 
comorbidity index (HCT-CI) was assessed as previously de- 
scribed [27]. Disease risk index (DRI) was calculated for pa- 
tients who underwent Haplo-Tx as first transplant with the 
exception of 2 with rare diseases (blastic plasmocytoid den- 
dritic cell neoplasm and plasmablastic lymphoma) [28]. All 
patients gave written informed consent to the proposed treat- 
ment and to the use of medical records for research purposes. 
The study was approved by the Center Ethical Committee and 
conducted according to the Declaration of Helsinki. 
 
Definition of haplo-identical donor 
 
HLA-typing was performed at high resolution level at HLA- 
A, HLA-B, HLA-C, HLA-DRB1, and HLA-DQB1 loci. A 
haplo-identical donor was defined as a family donor with a 
shared haplotype and at least two HLA-mismatches at the 
allele level on the unshared haplotype [29]. 
Patients; Haplo-Tx 70; 71 
Median age, years (range) 49 (21–70) 
Male 36 (51%) 
Hematological disease 
AML 47 (67) 
ALL-B, ALL-T 9 (13) 
Aggressive NHL 6 (9) 
MDS 3 (4) 
CLL 1 (1) 
CML-BC 2 (3) 
BPDCN 2 (3) 
Disease risk index (DRI)
a
 
Intermediate 34 (48.5) 
 
High/very high 20 (28.5) 
Not applicable 16 (23) 
2nd allogeneic transplant
b
 12 (17) 
3rd allogeneic transplant
b
 2 (3) 
Sequential therapy 22 (31) 
HCT-CI ≥ 3b 
Conditioning regimen
b
 
34(48) 
Thiotepa + busulfan + fludarabine 46(65) 
Thiotepa + melphalan + fludarabine 2 (3) 
Fludarabine + TBI 12 Gy 2 (3) 
Fludarabine + cyclophosphamide + TBI 2 Gy 19 (27) 
Fludarabine + melphalan + TBI 2 Gy 1 (1) 
Fludarabine 1 (1) 
GVHD prophylaxis
b
  
Tacrolimus + MMF + PT Cy 50 mg/kg +3/+4 66 (93) 
CSA + MMF + PT Cy 50 mg/kg +3/+5 4 (7) 
Stem cell source BM/PBSC
b
 42 (59) / 29 (41) 
Median donor age, years (range) 38 (16–66) 
Haplo-Tx haplo-identical transplant, AML acute myeloid leukemia, ALL 
acute lymphoblastic leukemia, NHL non-Hodgkin lymphoma, MDS 
myelodysplastic syndromes, CLL chronic lymphocytic leukemia, CML- 
BC chronic myeloid leukemia–blastic crisis, BPDCN blastic 
plasmocytoid dendritic cell neoplasia, HCT-CI hematopoietic cell trans- 
plantation comorbidity index, TBI total body irradiation, GVHD graft 
versus host disease, MMF mycophenolate mofetil, PT Cy post- 
transplantation cyclophosphamide, CSA cyclosporine A, ATG anti- 
thymocyte globulin, BM bone marrow, PBSC peripheral blood stem cells 
a 
Calculated for patients at 1st Haplo-Tx 
b 
Calculated on 71 transplants 
 
Transplantation and graft vs. host disease 
prophylaxis 
 
Bone marrow (BM) was used as stem cell source in 42/71 
(59%) transplants and granulocyte-colony stimulating factor 
(G-CSF) mobilized peripheral blood stem cells (PBSC) in 29/ 
71 (41%). Target cell doses were ≥ 3× 108 total nucleated 
  
 
cells (TNCs) for BM and ≥ 5× 106 CD34+ cells/kg for PBSC. 
Conditionings employed are illustrated in Table 1. GVHD 
prophylaxis consisted of PT-Cy 50 mg/kg on days + 3 and + 
4, tacrolimus and mycophenolic acid (MMF) from day + 5 in 
66/71 transplants (93%). Four out of 71 (6%) enrolled in a 
multicenter clinical trial received PT-Cy 50 mg/kg on days + 3 
and + 5 plus, cyclosporine from day − 1 and MMF from day + 
1 as per protocol. MMF was stopped at days + 35 and + 28, 
respectively. Tacrolimus and cyclosporine were tapered off by 
day +180 in the absence of GVHD. Acute and chronic GVHD 
were diagnosed according to standard criteria [30, 31]. 
 
Supportive care and infection control 
 
All patients received daily G-CSF from the day after the second 
PT-Cy infusion until absolute neutrophil count (ANC) engraft- 
ment. During neutropenia, patients received prophylactic quino- 
lones or cephalosporins. Antifungal prophylaxis included flucon- 
azole in 11/71 (15%) patients and echinocandins in 48/71 (66%) 
(micafungin in 46/48, caspofungin in 2/48). Moreover, 12/71 
(17%) patients received secondary antifungal prophylaxis with 
mold-active triazoles (voriconazole in 6/12, posaconazole in 3/ 
12) or liposomal amphotericin-B (in 3/12). Long-term prophy- 
laxis against herpes virus and Pneumocystis jirovecii was per- 
formed in all patients. Preemptive antiviral therapy was initiated 
when a cytomegalovirus (CMV) DNA viral load ≥ 10.000 
copies/ml by polymerase chain reaction assay was detected in 
peripheral blood. Diagnosis of invasive fungal infections (IFI) 
was defined according to the revised European Organization 
for Research and Treatment of Cancer/Mycoses Study Group 
(EORTC/MSG) definitions [32]. 
 
Statistical analysis 
 
Primary end-points were overall survival (OS) and event-free 
survival (EFS). OS was defined as the time from transplant to 
death from any cause, while EFS as the time from transplant to 
progression/relapse/death from any cause, whichever oc- 
curred first. Alive patients were censored at the date of last 
contact (04/30/2017). Patients who received more than one 
transplant were censored as alive at the date of the second/ 
third transplant. Survival curves were estimated by the 
Kaplan-Meier method and compared using the log-rank test. 
The composite end point of GVHD-free/relapse-free survival 
(GRFS) after transplant was calculated as described by Holtan 
et al. [33]; OS and EFS were also analyzed by the Cox pro- 
portional hazards model, comparing the two arms by the Wald 
test and calculating 95% confidence intervals. The following 
covariates were tested as risk factors: donor age (≥ 40 vs. < 
40 years), recipient age (≥ 40 vs. < 40 years), donor/recipient 
sex-mismatch (female into male vs. other), disease status at 
transplant (active disease vs. complete remission (CR), pa- 
tients who received SeqTh were considered with active 
disease), time from diagnosis to transplant (> 1 vs. ≤ 1 year), 
HCT-CI (≥ 3 vs. 0–2), stem cell source (bone marrow vs. 
peripheral blood), median cell doses infused/recipient weight 
(≥ 7.3 × 106 CD34+/kg vs. < 7.3 × 106 CD34+/kg, or ≥ 4.6 × 
10
8
 TNC/kg vs. < 4.6 × 10
8
/kg TNC/kg), intensity of the 
conditioning (non-myeloablative/reduced intensity vs. 
myeloablative) [34], DRI. Cumulative incidence (CI) analyses 
were calculated for the following events: acute GVHD [com- 
peting events (CE): relapse/death without acute GVHD); 
chronic GVHD (CE: relapse/death without chronic GVHD); 
NRM (CE: relapse), RI (CE: death without relapse), neutro- 
phil (ANC) and platelet (PLT) engraftment by stem cell source 
(CE: death without engraftment), CMV reactivation (CE: 
death without CMV reactivation), and IFI occurrence (CE: 
relapse/death without IFI). CI was estimated by the Gray test 
and by the competing risks regression model comparing the 
risk factors by the Fine-Gray test [35, 36]. Patient characteris- 
tics were tested using the Fisher’s exact test for categorical 
variables and the Mann-Whitney test for continuous ones. 
All results for continuous variables were expressed as median 
(range). All reported p values were obtained by the two-sided 
exact method, at the conventional 5% significance level. Data 
were analyzed as of May 2017 by R 3.2.3 (R Foundation for 
Statistical Computing, Vienna-A, http://www.R-project.org). 
 
 
Results 
 
Donor selection and study population 
 
An unrelated donor search was initially started for 53/70 pa- 
tients (76%). Twenty-seven did not find a suitable donor while 
18 (34%) relapsed during the donor search and underwent 
Haplo-Tx. For 17/70 (24%) patients, a donor search was not 
started because of age older than 65 years (n = 4), disease 
progression (n = 4), or graft failure (n = 1) after a first allograft 
from a sibling donor, very aggressive or refractory disease 
(n = 8) requiring an urgent transplant. Overall, 13 patients 
for a total of 14 transplants underwent Haplo-Tx as second 
or third allograft due to prior graft failure after Haplo-Tx (n = 
1) or disease relapse after a previous allograft from UCB units, 
sibling, or unrelated donors (n = 12). 
Median donor age was 38 years (range 16–66). Haplo- 
identical donors were offspring in 34/71 (48%) transplants, 
siblings in 21/71 (30%), parents in 15/71 (21%), and a 
first-degree cousin in 1/71 (1%). Female donor into male re- 
cipient was used in 19/71 (27%) transplants. Forty-seven/71 
(66%) recipient/donor pairs were fully allele-mismatched on 
the unshared haplotype, 15/71 (21%) had 4 mismatches, and 
9/71 (13%) ≤ 3. 
Thirty-one/70 (44%) patients, including those who 
underwent SeqTh, had active disease at the time of transplant. 
HCT-CI was ≥ 3 in 48%. Median time from diagnosis to 
  
 
Haplo-Tx as first transplant (n = 56) was 7.5 months (range 
2.9–114 months). 
 
Cell doses and engraftment 
 
Median cell doses infused were 5.9 × 10
8
/kg TNC (range 1.8– 
20.0 × 10
8
/kg) and 7.3 × 10
6
 CD34+/kg (range 4.1–15.5 × 
10
6
/kg) for BM and PBSC, respectively. No statistically sig- 
nificant differences were observed in CI of acute GVHD, 
chronic GVHD, ANC, and PLTS engraftment comparing pa- 
tients who received graft with cell doses above or below the 
median. Median ANC recovery occurred on day + 18 (range 
14–24 days) for BM and on day + 15 (range 9–20 days) for 
PBSC (p = 0.001). Median PLTS recovery occurred on day + 
27 (range 12–347) for BM and on day + 21 (range 10–192) for 
PBSC (p = 0.004). CI of ANC recovery at day + 30 were 
97.6% for BM, and 86.2% for PBSC (p = 0.535); CI of 
PLTS at days + 30, + 60, and + 90 were 58.5, 73.2, and 
78.9% for BM, and 69, 72.4, and 76% for PBSC (p = 0.434). 
 
Acute and chronic GVHD 
 
Overall CI of acute grade II-IV GVHD was 45% at day + 100 
(Fig. 1a), whereas grade III–IV acute GVHD was 11% at day 
+ 100. Median day of onset of acute GVHD was day 25 (range 
7–100). CI of acute GVHD was significantly higher in pa- 
tients who received PBSC versus BM (69 vs. 29%, p < 
0.001). Day-400 CI of overall chronic GVHD and moderate- 
severe chronic GVHD were 38.5 and 15%, respectively (Fig. 
1b); median day of onset was day + 196 (range 104–340). 
Overall, chronic GVHD was mild, moderate, and severe in 
12/20 (60%), 4/20 (20%), and 4/20 (20%) of the evaluable 
patients. CI of overall chronic GVHD was 33.8% in patients 
who received PBSC and 38.2% in BM (p = 0.753). One-year 
GRFS of 56 patients who received Haplo-Tx as first allograft 
was 30.5% (Fig. 1c). 
 
Infections 
 
Median day of CMV reactivation was day + 40 (range  23– 
152) in 38/70 (54%) patients. Six/38 (15%) had multiple 
CMV reactivations (range 2–4). No CMV disease occurred. 
CI of CMV reactivation was 53% at 3 months. Four/70 (6%) 
showed Epstein-Barr virus (EBV) reactivation. Hemorragic 
cystitis developed in 12/70 (17%) at a median of day +43 
(range 31–102); BK viruria was detected in 10/12 (83%). 
Overall, 15/70 (21%) experienced IFI, probable in 14/15 and 
proven in 1/15. Proven IFI was caused by Aspergillus 
fumigatus and Aspergillus terreus detected by bronchoalveo- 
lar lavage culture. Median time of onset was day + 73 (range 
3–575). Breakthrough IFI was observed in 4% of the patients 
who received mold-active prophylaxis and 27% in those who 
received fluconazole. CI of probable-proven IFI was 20 and 
 
 
Fig. 1 a Cumulative Incidence of acute grade II-IV GVHD and grade III– 
IV GVHD at day100 (71 transplants). b Cumulative Incidence of overall 
chronic GVHD and moderate-severe chronic GVHD at day400 (71 
transplants). c BGVHD relapse-free survival^ (GRFS) (56 patients who 
received Haplo-Tx as first allograft) 
 
 
22% at 12 and 24 months. By Gray test, the development of 
IFI was not influenced by age (p = 0.051), acute grade II–IV 
GVHD (yes vs. no, p = 0.566), acute grade III–IV GVHD (yes 
vs. no, p = 0.229), and chronic GVHD (yes vs. no, p = 0.694), 
conditioning regimen (non-myeloablative/reduced intensity 
vs. myeloablative, p = 0.839), and stem cell source (BM vs. 
PBSC, p = 0.966). 
  
 
Clinical outcomes 
 
Median OS and EFS were 24 and 14.5 months (Fig. 2a). 
Thirty-four out of 70 (48.5%) patients died. Median 
follow-up of survivors was 29.2 months (range 1.4– 
71.2 months). Median follow-up was 42.2 months (range 
1.4–71.2) and 23.7 months (range 3.2–59) for patients re- 
ceiving BM and PBSC, respectively. Three-year OS and 
EFS were 43.8 and 40.2%. For patients in CR (n = 40) at 
the time of Haplo-Tx, median OS and EFS were not reached 
at a follow-up of 29.2 months. Three-year OS was 54.6%, 
3-year EFS was 52.3% (Fig. 2c). No statistically significant 
differences in OS and EFS were observed in patients who 
received myeloablative vs. non-myeloablative/reduced in- 
tensity conditionings (53.5 vs. 48.0%, p = 0.515, and 42.4 
vs. 35.9%, p = 0.283, at 2 years respectively), or PBSC vs. 
BM (60.3 vs. 47.5%, p = 0.586, and 55.3 vs. 32.7%, p = 
0.257, at 2 years, respectively). By univariate analysis, only 
DRI had a significant impact on OS (Table 2). A formal 
multivariate analysis was not performed given the sample 
size of our cohort. 
CI of NRM was 25, 27, and 27% at 1, 2, and 3 years 
post-Haplo-Tx, respectively, whereas cumulative RI was 
22, 33, and 33% at 1, 2, and 3 years (Fig. 2b). Three-year 
RI was significantly lower in patients in CR at the time     
of transplant (21.5 vs. 48%, p = 0.009) and in patients 
who received PBSC as  stem  cell  source (22 vs. 45%, 
p = 0.009). 
 
Sequential high-dose chemotherapy and haplo-identical 
transplant 
 
Overall, 22/70 (31%) high-risk patients were transplanted dur- 
ing the chemo-induced neutropenia after high-dose salvage 
chemotherapy (Table 3). Conditioning, myeloablative in 14/ 
22 (64%) and non-myeloablative in 8/22 (36%), was started at 
a median of 9 days (range 4–15) after the last day of chemo- 
therapy. Six/22 (27%) had received a previous allograft. BM 
was used as stem cell source in 18/22 (82%) patients. All 
patients but 2, who presented with blast crisis of chronic my- 
eloid leukemia, suffered from refractory (n = 12) or secondary 
AML (n = 8). One/22 patients (4%) experienced primary graft 
 
 
 
 
Fig. 2 a Overall survival (OS) and event-free survival (EFS) and b 
relapse incidence (RI) and non-relapse mortality (NRM) of the entire 
patient population (71 patients). c OS and EFS of 40 patients who were 
in complete remission at the time of Haplo-Tx. d OS and EFS of 22 
patients who received sequential chemotherapy and allografting 
  
 
Table 2 Univariate analysis 
 
 
OS 
   
EFS 
 
HR 95% CI p 
 
HR 95% CI p 
HCT-CI (≥ 3 vs. 0–2) 1.01 0.50–2.04 0.986 
 
1.09 0.56–2.12 0.805 
Conditioning regimen (myeloablative vs. 1.27 0.62–2.61 0.517  1.44 0.74–2.8 0.288 
non-myeloablative)        
DRI (high/very high vs. intermediate) 2.36 1.07–5.22 0.034    
Donor/recipient sex match (F/M vs. other) 1.21 0.58–2.53 0.612 1.20 0.60–2.41 0.614 
Stem cell source (BM vs. PBSC) 1.22 0.59–2.51 0.587 1.48 0.75–2.91 0.262 
OS overall survival, EFS event-free survival, HR hazard ratio, 95% CI 95 % confidence interval, HCT-CI 
hematopoietic cell transplantation comorbidity index, DRI disease risk index, F female, M male, PBSC peripheral 
blood stem cells, BM bone marrow 
 
failure and was successfully rescued with a second haplo- 
identical transplant from the same donor. Median follow-up 
of survivors was 50 months (range 5–69 months); 3-year OS 
was 19% (Fig. 2d), while 3-year RI and NRM were 52 and 
28%, respectively. At day + 100/+ 400, CI of grade II–IV 
acute GVHD and chronic GVHD were 40.9 and 33.6%, re- 
spectively (Table 4). A statistically significant difference in 
clinical outcomes was observed in patients who received 
myeloablative vs. non-myeloablative/reduced intensity condi- 
tionings (OS, p = 0.027; EFS, p = 0.007). 
 
Table 3 Characteristics of patients undergoing sequential chemotherapy and allografting 
 
Age Sex Status at Haplo HSCT Previous 
Allo HSCT 
Karyotype BM Blasts 
at Seq. Th. 
Reinduction 
regimen 
Rest days Conditioning 
regimen 
#1 58 F Refractory sAML from RAEB1 No Monosomal 25% MEC 9 TBF 
#2 21 F Refractory AML Yes inv(16), + 8 25% AMSA+ARA-C 4 FLU+CY+TBI 
#3 40 M Refractory AML Yes Normal 72% AMSA+ARA-C 10 FLU+CY+TBI 
#4 37 F Refractory AML Yes 11q23 mut 17% MEC 4 FLU+CY+TBI 
#5 34 M Refractory AML MDS related No t(3;3) 25% MEC 4 FLU+CY+TBI 
#6 50 F Refractory sAML from CMML-2 No Normal 43% IDA+HD ARA-C* 15 TBF 
#7 54 M Refractory AML MDS related No Monosomal 9% MEC 10 TBF 
#8 42 F Myeloid Blastic Crisis of CML No t(9;22) 34% MEC 9 TBF 
#9 41 F Refractory AML Yes Normal 6% CLOFA+ARA-C 6 FLU+CY+TBI 
#10 55 M Lymphoid Blastic Crisis of CML No t(9;22) 80% HAM 6 TBF 
#11 29 M Refractory AML No + 8 88% CLOFA+ARA-C 7 TBF 
#12 62 M Refractory sAML No -7q 32% CLOFA+ARA-C 8 TBF 
#13 60 F Refractory AML No Normal 10% MEC 6 TBF 
#14 46 F Refractory AML Yes Normal 21% CLOFA+ARA-C 9 FLU+MEL+TBI 
#15 53 M Refractory sAML from CNL No NA 20% MEC 15 TBF 
#16 51 F Refractory AML Therapy-Related No Normal 55% MEC 7 TBF 
#17 54 F Refractory AML MDS related No Monosomal 15% IDA+HD ARA-C* 12 TBF 
#18 48 M Refractory AML No inv(3) 17% CLOFA+ARA-C 10 TBF 
#19 53 F Refractory AML No Normal 50% MEC 11 TBF 
#20 41 M Refractory AML Yes Complex 15% MEC 11 FLU+CY+TBI 
#21 58 M Refractory AML No + 21 75% MEC 11 FLU+CY+TBI 
#22 23 M Refractory AML No Normal 52% FAM 11 TBF 
Reinduction regimens: MEC: mitoxantrone 6 mg/sqm day 1–4, etoposide 80 mg/sqm day 1–4, cytarabine 1 g/sqm day 1–4; AMSA+ARA-C: amsacrine 
100 mg/sqm day 1–3, cytarabine 2 g/sqm day 1–3; IDA+HD ARA-C: idarubicin 17.5 mg/sqm day 3 and day 10, cytarabine 3 g/sqm BID day 1–2 and 
day 8–9; CLOFA+ARA-C: clofarabine 40 mg/sqm day1–4, cytarabine 1 g/sqm day 1–4; HAM: cytarabine 3 g/sqm BID day 1–3, mitoxantrone 10 mg/ 
sqm day 1–3, FAM: fludarabine 25 mg/sqm day 1–5, cytarabine 2 g/sqm day 1–5, mitoxantrone 12 mg/sqm day 3–5 
AML acute myeloid leukemia, sAML secondary AML, RAEB1 refractory anemia with excess blasts-type 1, MDS myelodysplastic syndrome, CMML-2 
chronic myelomonocytic leukemia-type 2, CML chronic myeloid leukemia, CNL chronic neutrophilic leukemia, NA not available 
*Cyclosporine A 12-h IV infusion days 3 and 10 
  
 
Table 4 Outcome after sequential therapy approach 
 
 
N = 22 1 year 2 years 3 years 
PLTS engraftment did not statistically differ between patients 
who received grafts with TNC and CD34+ cell doses above or 
   below the infused median cell doses. Several reports focused 
Non-relapse mortality 28% 28% 28% on the impact of CD34+ cells on transplant outcomes with 
Relapse incidence 42% 52% 52% discordant results. After myeloablative conditionings and al- 
Overall survival 34.5% 24.6% 19% lografts from sibling donors, Przepiorka et al. reported that 
Event-free survival 30.3% 20.2% 20.2% doses higher than 8.2 × 10
6
 CD34+/kg correlated with in- 
 
Day + 100 Day + 400 
Grade II–IV acute GVHD 40.9% 
Grade III–IV acute GVHD 13.6% 
Chronic GVHD 33.6% 
Moderate/severe chronic GVHD 13.2% 
 
 
 
 
Discussion 
 
The use of PT-Cy has allowed the rapid expansion of unmanip- 
ulated TCR Haplo-Tx [12–19]. In our series, most patients 
initially received BM and more recently PBSC, given the high 
risk of relapse. ANC engraftment occurred on day + 18 with 
BM and on day + 15 with PBSC, while PLTS recovery oc- 
curred on day + 27 with BM and on day + 21 with PBSC and 
secondary failure of engraftment was mainly due to florid re- 
lapse [37]. Overall, life-threatening grade III–IV acute GVHD 
and moderate-severe chronic GVHD were 15 and 11%. CI of 
acute GVHD was higher in patients who received PBSC versus 
BM while no difference in CI of chronic GVHD was observed. 
Differences in median follow-up between the two patient co- 
horts prevent however from drawing definitive conclusions. Of 
note, 1-year GRFS in patients who received Haplo-Tx as first 
allograft was 30.5% (Fig. 1c). This finding is particularly en- 
couraging in heavily pretreated patients and is also a reliable 
surrogate of good quality of life. Overall, our findings are con- 
sistent with a larger EBMT registry study by Ruggeri et al. [26] 
where 451 patients with acute leukemias were analyzed. Use of 
PBSC rather than BM was significantly associated with in- 
creased risk of grade II–IV and III–IV acute GVHD while no 
differences were found in CI of chronic GVHD. A large US 
comparison on 681 patients with hematologic malignancy who 
underwent Haplo-Tx with PT-Cy and BM (n = 481) or PBSC 
(n = 190) grafts was also conducted [38]. Transplant outcomes 
were compared by graft type after adjusting for patient, disease, 
and transplant characteristics. ANC and PLTS engraftments 
were similar. Risk of grade II-IV and chronic GVHD was lower 
with BM as compared with PBSC. There were no differences in 
OS, with 2-year rates of 54 and 57% after BM and PBSC, 
respectively, and in NRM. Relapse risk was however higher 
after BM in patients with leukemia, but not with lymphoma. 
The authors conclude that both BM and PBSC grafts are suit- 
able for Haplo-Tx though patterns of treatment failure differ. 
Cell doses may play a role in clinical outcomes. In our 
study, CI of acute GVHD, chronic GVHD, neutrophil and 
creased risk of grade II–IV acute GVHD while Zaucha et al. 
reported an increased risk of chronic GVHD with doses higher 
than 8 × 10
6
 CD34+/kg [39, 40]. By contrast, two registry 
studies from the National Marrow Donor Program (NMDP) 
and the Center for International Blood and Marrow Transplant 
Research (CIBMTR) showed that CD34+ cell doses respec- 
tively higher than 4.5 × 10
6
 and 6 × 10
6
/kg correlated with 
reduced NRM and improved OS [41, 42]. Recently, Czerw 
et al. reported that doses higher than 8.25 × 10
6
 CD34+/kg 
were associated with increased risk of grade III–IV GVHD, 
but had no significant impact on NRM, leukemia relapse, 
incidence of chronic GVHD, and OS in leukemia patients 
undergoing reduced-intensity allografting from unrelated do- 
nors [43]. Discrepancies are probably due to different disease 
categories, disease status at transplant, donor type, intensity of 
the conditioning, and GVHD prophylaxis. No prospective 
dose finding study on the impact of cell doses/graft composi- 
tion on clinical outcomes has so far been reported. 
We observed viral reactivation but no life-threatening viral 
disease. CMV reactivated especially during the first 3 
months post-transplant, but no CMV disease occurred [44]. 
Prospective monitoring of EBV DNA in blood is an institu- 
tional standard at our center while prophylaxis to prevent EBV 
reactivation is not given. Only 6% of our patients showed 
EBV reactivation. All patients remained asymptomatic and 
no post-transplant lymphoproliferative disorder was observed 
[45]. Hemorrhagic cystitis developed in 17% and most pa- 
tients concomitantly showed BK viruria. Other viruses such 
as adenovirus and JC virus were not detected in the urine, and 
no major kidney complications were observed [46, 47]. 
Haplo-Tx patients are at high risk of developing IFI. 
Twenty-one percent of our patients developed fungal infec- 
tions. Late infections were observed after mold-active primary 
prophylaxis had been stopped. A prospective evaluation of 
longer administration of mold active agents may be helpful. 
Interestingly, 31% of our patients underwent a sequential 
approach—chemotherapy and allografting—to timely treat 
aggressive high-risk leukemia. Moreover, almost a third (6/ 
22, 27%) had received a previous allograft. The sequential 
approach to treat myeloid malignancies was initially described 
by Schmid et al. [48–50]. In a prospective study, the combi- 
nation of fludarabine, cytarabine, and amsacrine (FLAMSA) 
followed by reduced-intensity allografting from HLA- 
matched sibling or unrelated donors was associated with 2-
year OS and 2-year EFS of 42 and 40% in 75 high-risk 
patients. More recently, Ringden et al. reported an outcome 
  
 
analysis on 267 patients with relapse/refractory AML who 
received sequential chemotherapy including fludarabine, 
cytarabine, and amsacrine followed by a reduced-intensity 
allograft from 77 HLA-matched siblings and from 190 
HLA-matched unrelated donors [51]. Incidence of acute grade 
II–IV and chronic GHVD was 32.1 and 30.2%, respectively. 
Three-year probability of NRM was 25.9%, of relapse 48.5%, 
of GRFS 17.8%, and of leukemia-free survival 25.6%. To our 
knowledge, we report on the largest experience of a sequential 
approach including Haplo-Tx. Outcomes of 30 refractory leu- 
kemia patients, where seven received intensive chemotherapy 
before Haplo-Tx, were described by Devillier et al. [52]. 
Overall and progression-free survivals were 37 and 32%. Of 
the seven patients who received a sequential approach, two 
were alive in CR at 11 and 14 months after Haplo-Tx. Though 
our cohort is relatively small, at a median follow-up of 
50 months, 3-year OS was 19%. A survival advantage was 
seen with myeloablative conditionings. However, it is impor- 
tant to point out that some patients treated with non- 
myeloablative/reduced intensity regimens had also received 
a prior allograft increasing the risk of toxicity. A formal com- 
parison between matched sibling versus unrelated donor or 
haplo-identical donor transplants has not been reported in this 
setting. However, Schmid et al. [49] observed a reduced risk 
of death from leukemia with transplant from unrelated donors. 
However, given a higher risk of non-relapse mortality, this 
finding did not translate into better OS as compared with 
transplants from HLA-matched sibling donor. 
In retrospective analyses, outcomes of Haplo HSCT with 
PT-Cy appeared similar to those reported after HLA-matched 
sibling or unrelated donor transplants [53–57]. However, re- 
sults should be validated in prospective randomized trials to 
avoid the inevitable limitations of retrospective comparisons. 
When compared with UCB transplants, Haplo HSCT with 
PT-Cy also showed equal or even better results either in ret- 
rospective and parallel prospective studies [58, 59]. A large 
multicenter phase III randomized trial comparing double unit 
UCB versus Haplo-Tx is currently ongoing (ClinicalTrials. 
gov: NCT01597778). Our donor selection policy has not 
changed over the study period. Our Bhierarchical^ selection 
includes first a HLA-identical sibling, second a fully or a 7/8 
allele matched unrelated donor and third a haplo-identical 
family donor. Although Pidala et al. recently reported that 
only 5% of patients take longer than 59 days to find a suitable 
unrelated donor [60], an allograft may not be delayed espe- 
cially in patients with refractory/relapsed malignancies. At our 
center, during the study period, 114 allografts from HLA- 
identical siblings and 212 from unrelated donors were per- 
formed. We estimate that with the implementation of the 
Haplo-Tx program, 15–20% of our patients who would not 
have found a suitable donor underwent a potentially curative 
allograft. However, our strategy by no means allows an unbi- 
ased comparison of clinical outcomes by donor type given the 
heterogeneity of patient cohorts and selection criteria. Thus, 
we strongly support the design of large multicenter prospec- 
tive trials in the near future where clinical outcomes by donor 
type may reliably be compared and potential selection bias be 
reduced. 
In summary, Haplo-Tx with PT-Cy is feasible in high-risk, 
heavily pretreated patients and can safely be part of a sequen- 
tial Bchemotherapy and allografting^ approach. Prospective 
comparisons of long-term clinical outcomes by different do- 
nor types are eagerly awaited. 
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